

Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma

Zhichao Tian (✉ tianzhichaoyy@163.com)

Henan Cancer Hospital <https://orcid.org/0000-0003-1058-2967>

Fan Zhang

Henan Cancer Hospital

Po Li

Henan Cancer Hospital

Jiaqiang Wang

Henan Cancer Hospital

Jinpo Yang

Henan Cancer Hospital

Peng Zhang

Henan Cancer Hospital

Weitao Yao

Henan Cancer Hospital

Xin Wang

Henan Cancer Hospital

Research article

Keywords: albumin-bound paclitaxel; gemcitabine; soft tissue sarcoma; epithelioid sarcoma; chemotherapy

Posted Date: May 7th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-23150/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published on July 30th, 2020. See the published version at <https://doi.org/10.1186/s12885-020-07199-0>.

Abstract

Background: The evidence that albumin-bound paclitaxel (nab-paclitaxel) is safe and efficacious for the treatment of many types of malignant tumors is continuously increasing. However, the clinical data and evidence of nab-paclitaxel and gemcitabine in metastatic soft tissue sarcoma (STS) treatment are rare.

Methods: The data of 17 patients with metastatic STS who received nab-paclitaxel/ gemcitabine chemotherapy between January 2019 and February 2020 were retrospectively reviewed. All patients were treated with nab-paclitaxel/ gemcitabine only after doxorubicin-based chemotherapy had failed. We evaluated the median progression-free survival (m-PFS), disease control rate (DCR), objective response rate (ORR) and adverse events (AEs) in these patients.

Results: The m-PFS was 6 months (95% CI, 2–9 months), ORR was 41.2% and DCR was 70.6%. The average change in target lesion diameter from baseline was $-19.06 \pm 45.74\%$. While the majority of the treatment patients experienced grade 1 or 2 AEs, grade 3 or 4 AEs were not common, but included neutropenia (17.6%), fatigue (11.8%), anemia (11.8%), leukopenia (11.8%), nausea (5.9%), peripheral neuropathy (5.9%), diarrhea (5.9%), and thrombocytopenia (5.9%). No treatment-related deaths occurred.

Conclusion: Nab-paclitaxel/ gemcitabine combination chemotherapy is comparatively effective in the treatment of STS, demonstrates low toxicity, and is worthy of further study.

Background

Soft tissue sarcomas (STS) comprise a diverse family of malignancies predominantly of mesodermal origin. Although the incidence of STS is low, there are still more than 40000 new cases in China each year.^[1] After standard treatment is completed, most cases of STS eventually progress into locally unresectable or metastatic advanced STS. The first-line treatment for unresectable and metastatic STS is doxorubicin-based chemotherapy, with an expected overall response rate (ORR) of 11–26% and a median progression-free survival (m-PFS) of 4–8 months.^[2, 3] Docetaxel/ gemcitabine is another common chemotherapy regimen, often considered a second-line treatment (after doxorubicin), with an expected ORR and an m-PFS similar to those of doxorubicin.^[4, 5] Multi-target receptor tyrosine kinase inhibitors (TKIs) and programmed cell death protein 1 (PD-1) inhibitors have also been shown to be effective against STS, although with a lower ORR and m-PFS than those of doxorubicin and docetaxel/ gemcitabine.^[6, 7] Because of the limited ORR and m-PFS obtained with each of the above treatments, the overall survival for advanced STS is approximately only 16 months.^[8] Therefore, there is an urgent need for more effective drugs to treat STS.

Albumin-bound paclitaxel (nab-paclitaxel) is a new paclitaxel preparation with solvent-free, and was initially developed to overcome toxicities associated with the solvents used in conventional formulations and to potentially improve efficacy.^[9] Nab-paclitaxel has been shown to deliver a higher dose of paclitaxel to tumor lesions (compared to solvent-based paclitaxel formulations) and to decrease the incidence of serious toxicities, including severe allergic reactions.^[10, 11] To date, nab-paclitaxel has been approved by the United States Food and Drug Administration for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer, and metastatic pancreatic cancer.^[10, 12] Not only that, there is growing evidence that nab-paclitaxel is effective in the treatment of other malignant tumors,^[13, 14] including STS.^[15–17]

Since January 2019, advanced sarcoma patients have been treated in our hospital (a major sarcoma treatment center in central China) with nab-paclitaxel and gemcitabine. In this study, we retrospectively investigate patient outcomes and study the safety and effectiveness of nab-paclitaxel/ gemcitabine combination chemotherapy in STS treatment, with the aim of providing additional evidence to establish clinical study design and to support clinical treatment.

Methods

Patients and eligibility criteria

This was a single center retrospective study of patients who received nab-paclitaxel/ gemcitabine combination chemotherapy as treatment for STS between January 2019 and February 2020 at The Affiliated Cancer Hospital of Zhengzhou University. This study was approved by the Ethics Committee of The Affiliated Cancer Hospital of Zhengzhou University, and was conducted according to the tenets of the Declaration of Helsinki. All patients provided written informed consent for data collection and research purposes. The inclusion criteria were as follows: 1) histologically proven STS; 2) locally unresectable or multiple metastases; 3) treated with nab-paclitaxel/

gemcitabine chemotherapy; 4) measurable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1); 5) The clinical data are complete and can be statistically analyzed.

Treatment protocol

Patients were administered 300 mg/m² nab-paclitaxel via intravenous bolus on day 1, and 1250 mg/m² gemcitabine via intravenous bolus on days 1 and 8. The treatment regimen was repeated every 21 days, until manifestation of progressive disease (PD) or occurrence of an adverse event. AEs were evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.0). If patients developed grade 3 or 4 AEs, treatment was delayed until recovery. However, the treatment was terminated if the delay lasted more than two weeks.

Evaluation of effectiveness and safety

The baseline characteristics of all the STS patients enrolled in this study were reviewed. Treatment effectiveness was evaluated according to the RECIST (version 1.1) criteria every one or two months using either computed tomography or magnetic resonance imaging. The ORR, disease control rate (DCR), median progression-free survival (m-PFS) and AEs were then evaluated. ORR and DCR were defined based on RECIST (version 1.1). PFS was defined as the time from the first day of drug treatment to the day of the PD or death occurrence, whichever occurred first.

Statistical analyses

All data were analyzed using SPSS 21.0 software. The present study comprises a descriptive analysis. Quantitative variables are presented as numerical values (percentage) and medians (range). The corresponding figure was drawn using GraphPad Prism 5.0. PFS was calculated using the Kaplan-Meier method, with a 95% confidence interval (CI).

Results

Patient characteristics

A total of 17 STS patients treated with nab-paclitaxel/ gemcitabine were enrolled in this study. Basic patient characteristics are shown in Table 1. The cohort included 11 (64.71%) men and 6 (35.29%) women. The average patient age was 38.71 ± 17.35 years. All patients had stage IV disease. All patients were previously treated with doxorubicin-based or other chemotherapy. The primary tumor site varied significantly, and although primary tumor sites were distributed throughout the body, they were mainly situated in the extremities. The histological subtypes were also markedly different. The most common subtype being epithelioid sarcoma (n = 5), followed by angiosarcoma (n = 3), rhabdomyosarcoma (n = 3), undifferentiated pleomorphic sarcoma (n = 2), fibrosarcoma (n = 2), leiomyosarcoma (n = 1), and primitive neuroectodermal tumor (n = 1).

Table 1
Patient demographics and characteristics

Patient No.	Age (years)	ECOG PS	Histological subtype	Stage	Primary site	Metastatic site	Previous DOX chemotherapy	Response	PFS (Months)
1	22	0	Epithelioid sarcoma	IV	Extremities	Lung and bone	Yes	PR	6
2	30	1	Epithelioid sarcoma	IV	Extremities	Lung and lymph nodes	Yes	PR	11
3	31	1	Epithelioid sarcoma	IV	Extremities	Lung and bone	Yes	PR	6
4	25	0	Epithelioid sarcoma	IV	Extremities	Bone	Yes	SD	9
5	18	1	Epithelioid sarcoma	IV	Extremities	Lung	Yes	PD	1.5
6	24	1	Angiosarcoma	IV	Extremities	Bone	Yes	CR	12
7	36	0	Angiosarcoma	IV	Extremities	Lung	Yes	SD	8
8	63	0	Angiosarcoma	IV	Extremities	Lung	Yes	PR	7
9	29	0	Rhabdomyosarcoma	IV	Head	Lung and Soft tissue	Yes	PR	9
10	22	0	Rhabdomyosarcoma	IV	Trunk	Bone	Yes	SD	6
11	33	0	Rhabdomyosarcoma	IV	Extremities	Lung	Yes	PD	3
12	65	1	UPS	IV	Extremities	Lung	Yes	SD	6
13	58	0	UPS	IV	Pelvis	Lung	Yes	PD	1.3
14	64	1	Fibrosarcoma	IV	Trunk	Lung	Yes	PR	9
15	61	0	Fibrosarcoma	IV	Extremities	Lung	Yes	PD	1
16	52	0	Leiomyosarcoma	IV	Extremities	Lung	Yes	PD	2
17	25	1	PNET	IV	Trunk	Lung	Yes	SD	3

Effectiveness of therapy

Of the 17 patients, 1 patient with angiosarcoma achieved complete response, 6 patients had partial response, 5 patients achieved stable disease (SD), and 5 patients had PD (Tables 1 and 2; Fig. 1). The ORR was 41.2%, the DCR was 70.6%, and the m-PFS was 6 months (95% CI, 2–9 months) (Table 3; Fig. 1). The average change in target lesion diameter from baseline was $-19.06 \pm 45.74\%$ (Fig. 1).

Table 2
Responses of various histological subtypes to treatment

Histological subtypes	Number of patients			
	CR	PR	SD	PD
Epithelioid sarcoma (n = 5)	0	3	1	1
Angiosarcoma (n = 3)	1	1	1	0
Rhabdomyosarcoma (n = 3)	0	1	1	1
UPS (n = 2)	0	0	1	1
Fibrosarcoma (n = 2)	0	1	0	1
Leiomyosarcoma	0	0	0	1
PNET	0	0	1	0
Total	1	6	5	5

Table 3
Clinical effectiveness

Characteristics	Data
ORR	41.20%
DCR	70.60%
M-PFS (months)	6 (95%CI: 2–9)

Toxicity and safety

In general, nab-paclitaxel/ gemcitabine chemotherapy was relatively well tolerated. As shown in Table 4, the most common grade 1 or 2 AEs were alopecia (88.2%, 15/17), neutropenia (64.7%, 11/17), fatigue (52.9%, 9/17), anemia (47.1%, 8/17), and nausea (41.2%, 7/17). The grade 3 or 4 AEs were not common, but included neutropenia (17.6%), fatigue (11.8%), anemia (11.8%), leukopenia (11.8%), nausea (5.9%), peripheral neuropathy (5.9%), diarrhea (5.9%), and thrombocytopenia (5.9%). No treatment-related deaths occurred.

Table 4
Adverse events

Adverse events	Grade 1–2	Grade 3–4
Alopecia	88.2% (15/17)	
Neutropenia	64.7% (11/17)	17.6% (3/17)
Fatigue	52.9% (9/17)	11.8% (2/17)
Anemia	47.1% (8/17)	11.8% (2/17)
Nausea	41.2% (7/17)	5.9% (1/17)
Leukopenia	35.3% (6/17)	11.8% (2/17)
Peripheral neuropathy	29.4% (5/17)	5.9% (1/17)
Anorexia	29.4% (5/17)	
Diarrhea	23.5% (4/17)	5.9% (1/17)
Thrombocytopenia	23.5% (4/17)	5.9% (1/17)
Alkaline phosphatase increased	17.6% (3/17)	
Fever	11.8% (2/17)	
Abdominal pain	11.8% (2/17)	
Pneumonitis	5.9% (1/17)	

Discussion

The taxanes (paclitaxel and docetaxel) represent a class of antineoplastic agents that interfere with microtubule function leading to altered mitosis and cellular death.[18] Paclitaxel is rarely used in the treatment of STS because it demonstrates limited efficacy.^[19] The main reason for the limited efficacy of paclitaxel is that there is a practical limitation to the delivered dose due to high toxicity.^[10, 20, 21] Docetaxel is generally considered to be less toxic than paclitaxel.^[22] However, the toxicity of docetaxel-based chemotherapy is still greater than that of doxorubicin-based chemotherapy. Thus, although the clinical efficacy of the two regimens is similar, docetaxel-based chemotherapy is considered as a second-line regimen for the treatment of advanced STS.^[4]

Important clinical problems related to treatment with paclitaxel and docetaxel include poor drug solubility, serious dose-limiting toxicities (including myelosuppression), peripheral sensory neuropathy, allergic reactions, and the eventual development of drug resistance.^[18] A number of these side effects are associated with the solvents used for the dilution of these antineoplastic agents: Cremophor EL for paclitaxel and polysorbate 80 for docetaxel.^[22] To solve these problems, nab-paclitaxel was developed to be free of the conventional surfactants used in the water-based injections. Nab-paclitaxel is a stable, negatively charged nanoparticle, approximately 0.1–0.2 µm in size, prepared by encapsulating paclitaxel in albumin nanoparticle.^[9] The albumin-bound paclitaxel can pass through the leaky capillary junctions in the tumor bed more easily than through the normal vessels in healthy tissue, and is thus taken up selectively by tumor tissues and cells. According to clinical data, nab-paclitaxel offers several improvements over conventional, solvent- and Cremophor-based paclitaxel, including lower toxicities, shorter administration time, higher efficacy, and the lack of a need for premedication.^[23] Several previous studies have demonstrated that nab-paclitaxel has greater efficacy and a more favorable safety profile (compared with solvent-based paclitaxel) in many malignancies.^[13, 24, 25]

To our knowledge, this study is the first to investigate the safety and effectiveness of nab-paclitaxel/ gemcitabine combination chemotherapy in patients with advanced STS. In this retrospective observational study, we observed that nab-paclitaxel was effective for the treatment of STS, with an ORR of 47.1%, and an m-PFS of seven months. Considering that all of these patients received nab-paclitaxel/ gemcitabine treatment following failed doxorubicin-based chemotherapy, the effectiveness of nab-paclitaxel/ gemcitabine chemotherapy is increased compared to doxorubicin-based chemotherapy and docetaxel/ gemcitabine combination therapy reported by other studies.^[2, 4] The toxicity of nab-paclitaxel/ gemcitabine is also lower than that of doxorubicin and docetaxel/ gemcitabine.^[4] In addition, the results of this study demonstrate that the effectiveness of nab-paclitaxel/ gemcitabine is significantly greater than that of conventional paclitaxel and docetaxel in some subtypes of STS, such as epithelioid sarcoma. Previous studies have demonstrated the

limited efficacy of conventional paclitaxel and docetaxel in the treatment of epithelioid sarcoma.^[26, 27] In the present study, three of the five epithelioid sarcoma patients achieved PR, and one patient achieved SD.

The results of our study indicate that nab-paclitaxel is more effective and has lower toxicity than conventional paclitaxel or docetaxel in STS. In view of the fact that nab-paclitaxel is superior to conventional paclitaxel in the treatment of many malignant tumors,^[13, 24, 25] nab-paclitaxel should not simply be considered as a drug with similar properties to paclitaxel. It should be regarded as a new chemotherapeutic drug; and the efficacy of this drug should be evaluated in various malignancies. For example, though paclitaxel is considered to be ineffective in the treatment of osteosarcoma,^[28] it should not be assumed that treatment of osteosarcoma with nab-paclitaxel is also ineffective. Indeed, we speculate that treatment of osteosarcoma with nab-paclitaxel may yield promising results.

This study provides preliminarily results demonstrating the safety and effectiveness of nab-paclitaxel/ gemcitabine in STS treatment. Although this study has some limitations, including the small sample size, retrospective design and the absence of a control group, we can still conclude that nab-paclitaxel/ gemcitabine combination chemotherapy used in STS treatment demonstrates promising effectiveness with low toxicity, and is worthy of further study. In view of the low toxicity and convenience of nab-paclitaxel, we believe that the combination of nab-paclitaxel and other anticancer drugs (chemotherapeutic drugs, TKIs, PD-1 inhibitors) in the treatment of STS may produce significant results. In elderly sarcoma patients, where effective treatment is wanting due to poor tolerance,^[29] nab-paclitaxel may be of significant benefit. Fortunately, several clinical trials on the efficacy of nab-paclitaxel in sarcomas are currently recruiting patients (Table 5). To further investigate the efficacy of nab-paclitaxel in the treatment of sarcoma, we are conducting a randomized clinical trial soon (Chinese Clinical Trial Registry NO. ChiCTR2000030250).

Table 5
Clinical trials of nab-paclitaxel in sarcomas currently recruiting.

Title	Phase	Status	Histological subtypes	Number of patients	Collaborators	Dates	NCT Number
Nab-paclitaxel and gemcitabine in advanced STS.	1 and 2	Recruiting	STS	45	Swiss Group for Clinical Cancer Research	Start: October 2018 Completion: October 2022	NCT03524898
Nab-paclitaxel and gemcitabine for recurrent/refractory sarcoma.	2	Recruiting	Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, STS	72	H. Lee Moffitt Cancer Center and Research Institute National Pediatric Cancer Foundation	Start: October 2016 Completion: March 2021	NCT02945800
Trial of nab-paclitaxel in patients with desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma.	2	Recruiting	Desmoid tumors, Desmoplastic small round cell tumors, Ewing sarcoma	61	Grupo Espanol de Investigacion en Sarcomas	Start: May 2017 Completion: September 2020	NCT03275818
Nab-paclitaxel in combination with gemcitabine for pediatric relapsed and refractory solid tumors.	1	Recruiting	Pediatric relapsed and refractory solid tumors	24	Emory University, Celgene Corporation	Start: August 2018 Completion: May 2022	NCT03507491

Conclusions

In conclusion, nab-paclitaxel/ gemcitabine combination chemotherapy is comparatively effective in STS treatment, demonstrates low toxicity, and is worthy of further study.

Abbreviations

Nab-paclitaxel: albumin-bound paclitaxel; STS: metastatic soft tissue sarcoma; m-PFS: median progression-free survival; DCR: disease control rate; ORR: objective response rate; AEs: adverse events; TKIs: receptor tyrosine kinase inhibitors; PD-1: programmed cell death protein 1; RECIST: Response Evaluation Criteria in Solid Tumors; PD: progressive disease; SD: stable disease; ECOG PS: Eastern Cooperative Oncology Group performance status; UPS: undifferentiated pleomorphic sarcoma; PNET: primitive neuroectodermal tumor; DOX: doxorubicin-based; PR: partial response; CR: complete response.

Declarations

Ethics approval and consent to participate

Because of the non-interventional, retrospective nature of analyzed data and because our analysis involved an anonymized dataset, neither ethical review nor informed consent of the patients was required.

Consent for publication

Not applicable.

Availability of data and materials

The data used in this study are abstracted from individual patient records and are not publicly available.

Competing interests

All authors have no conflict of interest to declare.

Funding

Not applicable.

Authors' contributions

ZT, FZ, PL, JW, JY, PZ, WY and XW performed patient recruitment and clinical investigation. ZT conceived of the study, participated in its design and coordination and helped draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank all Chinese patients and investigators who participated in this study.

References

1. Yang Z, Zheng R, Zhang S, Zeng H, Li H, Chen W. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. *Cancer Biol Med.* 2019; 16: 565-74.
2. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay J-Y, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. *The Lancet Oncology.* 2014; 15: 415-23.
3. Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. *The Lancet.* 2016; 388: 488-97.
4. Beatrice Seddon SJS, Jeremy Whelan, Michael Leahy, Penella J Woll, Fiona Cowie, Christian Rothermundt, Zoe Wood, Charlotte Benson, Nasim Ali, Maria Marples, Gareth J Veal, David Jamieson, Katja Küver, Roberto Tirabosco, Sharon Forsyth, Stephen Nash, Hakim-Moulay Dehbi, Sandy Beare. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated

- advanced unresectable or metastatic soft-tissue sarcomas (GeDDis): a randomised controlled phase 3 trial. *Lancet Oncol.* 2017; 18: 1397-410.
5. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. *J Clin Oncol.* 2007; 25: 2755-63.
 6. Wilding CP, Elms ML, Judson I, Tan AC, Jones RL, Huang PH. The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. *Expert Rev Anticancer Ther.* 2019; 19: 971-91.
 7. Tawbi HA, Burgess M, Bolejack V, Tine BAV, Schuetze SM. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. *Lancet Oncol.* 2017; 18: 1493-501.
 8. Meyer M, Seetharam M. First-Line Therapy for Metastatic Soft Tissue Sarcoma. *Current Treatment Options in Oncology.* 2019; 20.
 9. Fu Q, Sun J, Zhang W, Sui X, Yan Z, He Z. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. *Recent Pat Anticancer Drug Discov.* 2009; 4: 262-72.
 10. Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. *Drug Des Devel Ther.* 2015; 9: 3767-77.
 11. Kudlowitz D, Muggia F. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications. *Expert Opin Drug Saf.* 2014; 13: 681-5.
 12. .
 13. Ishikawa M, Iwasa S, Nagashima K, Aoki M, Imazeki H, Hirano H, et al. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis. *Invest New Drugs.* 2019.
 14. Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, et al. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial. *JAMA Oncol.* 2018; 4: 1707-12.
 15. Higuchi T, Kawaguchi K, Miyake K, Oshiro H, Zhang Z, Razmjooei S, et al. The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. *Biomed Pharmacother.* 2019; 111: 835-40.
 16. Hara N, Fujimoto N, Miyamoto Y, Yamagishi T, Asano M, Fuchimoto Y, et al. Angiosarcoma of the thoracic wall responded well to nanoparticle albumin-bound paclitaxel: A case report. *Drug Discov Ther.* 2016; 10: 114-6.
 17. Metts JL, Alazraki AL, Clark D, Amankwah EK, Wasilewski-Masker KJ, George BA, et al. Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas. *Pediatr Blood Cancer.* 2018; 65: e27246.
 18. Louage B, De Wever O, Hennink WE, De Geest BG. Developments and future clinical outlook of taxane nanomedicines. *J Control Release.* 2017; 253: 137-52.
 19. Nagar SP, Mytelka DS, Candrilli SD, D'Yachkova Y, Lorenzo M, Kasper B, et al. Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France. *Sarcoma.* 2018; 2018: 5467057.
 20. Nehate C, Jain S, Saneja A, Khare V, Alam N, Dubey RD, et al. Paclitaxel formulations: challenges and novel delivery options. *Curr Drug Deliv.* 2014; 11: 666-86.
 21. Alqahtani FY, Aleanizy FS, El Tahir E, Alkahtani HM, AlQuadeib BT. Paclitaxel. *Profiles Drug Subst Excip Relat Methodol.* 2019; 44: 205-38.
 22. Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. *Drug Des Devel Ther.* 2012; 6: 371-84.
 23. Cecco S, Aliberti M, Baldo P, Giacomini E, Leone R. Safety and efficacy evaluation of albumin-bound paclitaxel. *Expert Opin Drug Saf.* 2014; 13: 511-20.
 24. Lee H, Park S, Kang JE, Lee HM, Kim SA, Rhie SJ. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis. *Sci Rep.* 2020; 10: 530.
 25. Tan H, Hu J, Liu S. Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis. *Artif Cells Nanomed Biotechnol.* 2019; 47: 268-77.
 26. Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, et al. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. *JAMA Oncol.* 2018; 4: e180219.

27. Pink D, Richter S, Gerdes S, Andreou D, Tunn PU, Busemann C, et al. Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis. *Oncology*. 2014; 87: 95-103.
28. Patel SR, Papadopoulos NE, Plager C, Linke KA, Moseley SH, Spiridonidis CH, et al. Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. *Cancer*. 1996; 78: 741-4.
29. Jones RL. Sarcomas and old age: few options for such a large patient population. *Future Oncol*. 2019; 15: 11-5.

Figures




Figure 1

Waterfall plots showing the maximum percentage change in target lesion size during the treatment. Horizontal dashed lines represent the criteria for partial response (30% decrease in target lesion size) and progressive disease (20% increase in target lesion size), as evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1. Abbreviations: PFS, the progression-free survival; RECIST, the response evaluation criteria in solid tumors version 1.1; UPS, undifferentiated pleomorphic sarcoma; PNET, primitive neuroectodermal tumor.